Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc.
According to IQVIA sales data for the 12-month period ending April 2026, the Vimpat Injection market achieved annual sales of around $15.2 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries.
